Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients - a prospective study
Grenda R, Karczmarewicz E, Rubik J, Matusik H, Płudowski P, Kiliszek M, Piskorski J. Bone mineral disease in children after renal transplantation in steroid‐free and steroid‐treated patients – a prospective study. Pediatr Transplantation 2011: 15:205–213. © 2010 John Wiley & Sons A/S. : Bone di...
Gespeichert in:
| Veröffentlicht in: | Pediatric transplantation 2011-03, Vol.15 (2), p.205-213 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 213 |
|---|---|
| container_issue | 2 |
| container_start_page | 205 |
| container_title | Pediatric transplantation |
| container_volume | 15 |
| creator | Grenda, Ryszard Karczmarewicz, Elżbieta Rubik, Jacek Matusik, Halina Płudowski, Paweł Kiliszek, Małgorzata Piskorski, Jarosław |
| description | Grenda R, Karczmarewicz E, Rubik J, Matusik H, Płudowski P, Kiliszek M, Piskorski J. Bone mineral disease in children after renal transplantation in steroid‐free and steroid‐treated patients – a prospective study. Pediatr Transplantation 2011: 15:205–213. © 2010 John Wiley & Sons A/S.
: Bone disease may persist after transplantation. Different approaches aiming to ameliorate this problem have been investigated. The aim of the study was to compare the long‐term effect of three medical interventions: (i) two prophylactic oral doses of 50 mg ibandronate; (ii) daily oral dose of 0.25 μg of 1α‐OHD3 (both of these regimens in patients receiving steroids), and (iii) steroid minimization immunosuppressive protocol in patients with no other specific prophylaxis. Patients: A total of 37 children, at a mean age of 13.33 ± 3.49 yr, dialyzed for 15.93 ± 16.7 months before transplantation, were divided into three groups, depending on medical intervention. Bone mineral content and density (BMC, BMD, DXA), serum markers of bone resorption and formation (CTX, P1NP), calcium, phosphate, 25OHD3/1.25 (OH)2D3 and PTH concentration were evaluated during two yr of follow‐up. The mean values of BMD in the whole population and among the three subgroups remained within the age‐ and gender‐matched normal range during follow‐up. Patients from groups II (alphacalcidiol) and III (steroid minimization) showed a significant decrease in BMD Z‐scores over time, and this effect was determined with increasing age using multivariate analysis. Patients receiving two doses of ibandronate maintained unchanged Z‐scores for BMD and BMC over time. |
| doi_str_mv | 10.1111/j.1399-3046.2010.01448.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_923203080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>923203080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4698-26b88ec37921329c19d4df98a74a255de59a37cdc50ee70bb84b2523065963803</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0Eoh_wF5AviFMWf8b2BYlWbUFaKEJFHC3Hnggv2STYWdg98dfrdJflWh_s0cwzr8d-EcKULGhZb1cLyo2pOBH1gpGSJVQIvdg-QafHwtOHWFWcCnaCznJeEUJrocVzdMIoNaZsp-jvxdADXscekutwiBlcBhx77H_ELiTosWsnSLhEpT4l1-exc_3kpjj0M5dLdYihahMAdn04JqYEboKAx4JCP2VcYYfHNOQR_BR_QwE3YfcCPWtdl-Hl4TxH366v7i4_VMvbm4-X75eVF7XRFasbrcFzVabmzHhqggit0U4Jx6QMII3jygcvCYAiTaNFwyTjpJam5prwc_Rmr1sm-LWBPNl1zB668hYYNtkaxhnh5BGkllQoTdVM6j3py6tygtaOKa5d2llK7OyTXdnZDjvbYWef7INPdltaXx0u2TRrCMfGf8YU4PUBcNm7ri0f72P-z3EthdQz927P_Ykd7B49gP1ydfd1DotAtReIxbjtUcCln7ZWXEn7_fONJRdKfpLL0s7vAYB6vec</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>851478170</pqid></control><display><type>article</type><title>Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients - a prospective study</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Grenda, Ryszard ; Karczmarewicz, Elżbieta ; Rubik, Jacek ; Matusik, Halina ; Płudowski, Paweł ; Kiliszek, Małgorzata ; Piskorski, Jarosław</creator><creatorcontrib>Grenda, Ryszard ; Karczmarewicz, Elżbieta ; Rubik, Jacek ; Matusik, Halina ; Płudowski, Paweł ; Kiliszek, Małgorzata ; Piskorski, Jarosław</creatorcontrib><description>Grenda R, Karczmarewicz E, Rubik J, Matusik H, Płudowski P, Kiliszek M, Piskorski J. Bone mineral disease in children after renal transplantation in steroid‐free and steroid‐treated patients – a prospective study. Pediatr Transplantation 2011: 15:205–213. © 2010 John Wiley & Sons A/S.
: Bone disease may persist after transplantation. Different approaches aiming to ameliorate this problem have been investigated. The aim of the study was to compare the long‐term effect of three medical interventions: (i) two prophylactic oral doses of 50 mg ibandronate; (ii) daily oral dose of 0.25 μg of 1α‐OHD3 (both of these regimens in patients receiving steroids), and (iii) steroid minimization immunosuppressive protocol in patients with no other specific prophylaxis. Patients: A total of 37 children, at a mean age of 13.33 ± 3.49 yr, dialyzed for 15.93 ± 16.7 months before transplantation, were divided into three groups, depending on medical intervention. Bone mineral content and density (BMC, BMD, DXA), serum markers of bone resorption and formation (CTX, P1NP), calcium, phosphate, 25OHD3/1.25 (OH)2D3 and PTH concentration were evaluated during two yr of follow‐up. The mean values of BMD in the whole population and among the three subgroups remained within the age‐ and gender‐matched normal range during follow‐up. Patients from groups II (alphacalcidiol) and III (steroid minimization) showed a significant decrease in BMD Z‐scores over time, and this effect was determined with increasing age using multivariate analysis. Patients receiving two doses of ibandronate maintained unchanged Z‐scores for BMD and BMC over time.</description><identifier>ISSN: 1397-3142</identifier><identifier>EISSN: 1399-3046</identifier><identifier>DOI: 10.1111/j.1399-3046.2010.01448.x</identifier><identifier>PMID: 21199211</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Adolescent ; Age ; Age Factors ; Analysis of Variance ; Biological and medical sciences ; Bisphosphonates ; Bone Demineralization, Pathologic - diagnosis ; Bone Demineralization, Pathologic - drug therapy ; Bone Demineralization, Pathologic - etiology ; Bone Density - drug effects ; Bone Density - physiology ; bone disease ; Bone diseases ; Bone mineral content ; Bone mineral density ; Bone resorption ; Calcifediol - administration & dosage ; Calcium phosphate ; Child ; Children ; Cohort Studies ; Collagen ; Diphosphonates - administration & dosage ; Diseases of the osteoarticular system ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Dual energy X-ray absorptiometry ; Female ; Follow-Up Studies ; General aspects ; Humans ; Ibandronic acid ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Kidney transplantation ; Kidney Transplantation - adverse effects ; Kidney Transplantation - methods ; Long-term effects ; Male ; Medical sciences ; Multivariate Analysis ; Osteoporosis. Osteomalacia. Paget disease ; Parathyroid hormone ; Prophylaxis ; Prospective Studies ; renal transplantation ; Risk Assessment ; Sex Factors ; Steroid hormones ; steroid minimization ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Treatment Outcome</subject><ispartof>Pediatric transplantation, 2011-03, Vol.15 (2), p.205-213</ispartof><rights>2010 John Wiley & Sons A/S</rights><rights>2015 INIST-CNRS</rights><rights>2010 John Wiley & Sons A/S.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4698-26b88ec37921329c19d4df98a74a255de59a37cdc50ee70bb84b2523065963803</citedby><cites>FETCH-LOGICAL-c4698-26b88ec37921329c19d4df98a74a255de59a37cdc50ee70bb84b2523065963803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1399-3046.2010.01448.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1399-3046.2010.01448.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23854581$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21199211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grenda, Ryszard</creatorcontrib><creatorcontrib>Karczmarewicz, Elżbieta</creatorcontrib><creatorcontrib>Rubik, Jacek</creatorcontrib><creatorcontrib>Matusik, Halina</creatorcontrib><creatorcontrib>Płudowski, Paweł</creatorcontrib><creatorcontrib>Kiliszek, Małgorzata</creatorcontrib><creatorcontrib>Piskorski, Jarosław</creatorcontrib><title>Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients - a prospective study</title><title>Pediatric transplantation</title><addtitle>Pediatr Transplant</addtitle><description>Grenda R, Karczmarewicz E, Rubik J, Matusik H, Płudowski P, Kiliszek M, Piskorski J. Bone mineral disease in children after renal transplantation in steroid‐free and steroid‐treated patients – a prospective study. Pediatr Transplantation 2011: 15:205–213. © 2010 John Wiley & Sons A/S.
: Bone disease may persist after transplantation. Different approaches aiming to ameliorate this problem have been investigated. The aim of the study was to compare the long‐term effect of three medical interventions: (i) two prophylactic oral doses of 50 mg ibandronate; (ii) daily oral dose of 0.25 μg of 1α‐OHD3 (both of these regimens in patients receiving steroids), and (iii) steroid minimization immunosuppressive protocol in patients with no other specific prophylaxis. Patients: A total of 37 children, at a mean age of 13.33 ± 3.49 yr, dialyzed for 15.93 ± 16.7 months before transplantation, were divided into three groups, depending on medical intervention. Bone mineral content and density (BMC, BMD, DXA), serum markers of bone resorption and formation (CTX, P1NP), calcium, phosphate, 25OHD3/1.25 (OH)2D3 and PTH concentration were evaluated during two yr of follow‐up. The mean values of BMD in the whole population and among the three subgroups remained within the age‐ and gender‐matched normal range during follow‐up. Patients from groups II (alphacalcidiol) and III (steroid minimization) showed a significant decrease in BMD Z‐scores over time, and this effect was determined with increasing age using multivariate analysis. Patients receiving two doses of ibandronate maintained unchanged Z‐scores for BMD and BMC over time.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Age</subject><subject>Age Factors</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Bisphosphonates</subject><subject>Bone Demineralization, Pathologic - diagnosis</subject><subject>Bone Demineralization, Pathologic - drug therapy</subject><subject>Bone Demineralization, Pathologic - etiology</subject><subject>Bone Density - drug effects</subject><subject>Bone Density - physiology</subject><subject>bone disease</subject><subject>Bone diseases</subject><subject>Bone mineral content</subject><subject>Bone mineral density</subject><subject>Bone resorption</subject><subject>Calcifediol - administration & dosage</subject><subject>Calcium phosphate</subject><subject>Child</subject><subject>Children</subject><subject>Cohort Studies</subject><subject>Collagen</subject><subject>Diphosphonates - administration & dosage</subject><subject>Diseases of the osteoarticular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Dual energy X-ray absorptiometry</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Humans</subject><subject>Ibandronic acid</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Kidney transplantation</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Kidney Transplantation - methods</subject><subject>Long-term effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Multivariate Analysis</subject><subject>Osteoporosis. Osteomalacia. Paget disease</subject><subject>Parathyroid hormone</subject><subject>Prophylaxis</subject><subject>Prospective Studies</subject><subject>renal transplantation</subject><subject>Risk Assessment</subject><subject>Sex Factors</subject><subject>Steroid hormones</subject><subject>steroid minimization</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Treatment Outcome</subject><issn>1397-3142</issn><issn>1399-3046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhi0Eoh_wF5AviFMWf8b2BYlWbUFaKEJFHC3Hnggv2STYWdg98dfrdJflWh_s0cwzr8d-EcKULGhZb1cLyo2pOBH1gpGSJVQIvdg-QafHwtOHWFWcCnaCznJeEUJrocVzdMIoNaZsp-jvxdADXscekutwiBlcBhx77H_ELiTosWsnSLhEpT4l1-exc_3kpjj0M5dLdYihahMAdn04JqYEboKAx4JCP2VcYYfHNOQR_BR_QwE3YfcCPWtdl-Hl4TxH366v7i4_VMvbm4-X75eVF7XRFasbrcFzVabmzHhqggit0U4Jx6QMII3jygcvCYAiTaNFwyTjpJam5prwc_Rmr1sm-LWBPNl1zB668hYYNtkaxhnh5BGkllQoTdVM6j3py6tygtaOKa5d2llK7OyTXdnZDjvbYWef7INPdltaXx0u2TRrCMfGf8YU4PUBcNm7ri0f72P-z3EthdQz927P_Ykd7B49gP1ydfd1DotAtReIxbjtUcCln7ZWXEn7_fONJRdKfpLL0s7vAYB6vec</recordid><startdate>201103</startdate><enddate>201103</enddate><creator>Grenda, Ryszard</creator><creator>Karczmarewicz, Elżbieta</creator><creator>Rubik, Jacek</creator><creator>Matusik, Halina</creator><creator>Płudowski, Paweł</creator><creator>Kiliszek, Małgorzata</creator><creator>Piskorski, Jarosław</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>201103</creationdate><title>Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients - a prospective study</title><author>Grenda, Ryszard ; Karczmarewicz, Elżbieta ; Rubik, Jacek ; Matusik, Halina ; Płudowski, Paweł ; Kiliszek, Małgorzata ; Piskorski, Jarosław</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4698-26b88ec37921329c19d4df98a74a255de59a37cdc50ee70bb84b2523065963803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Age</topic><topic>Age Factors</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Bisphosphonates</topic><topic>Bone Demineralization, Pathologic - diagnosis</topic><topic>Bone Demineralization, Pathologic - drug therapy</topic><topic>Bone Demineralization, Pathologic - etiology</topic><topic>Bone Density - drug effects</topic><topic>Bone Density - physiology</topic><topic>bone disease</topic><topic>Bone diseases</topic><topic>Bone mineral content</topic><topic>Bone mineral density</topic><topic>Bone resorption</topic><topic>Calcifediol - administration & dosage</topic><topic>Calcium phosphate</topic><topic>Child</topic><topic>Children</topic><topic>Cohort Studies</topic><topic>Collagen</topic><topic>Diphosphonates - administration & dosage</topic><topic>Diseases of the osteoarticular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Dual energy X-ray absorptiometry</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Humans</topic><topic>Ibandronic acid</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Kidney transplantation</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Kidney Transplantation - methods</topic><topic>Long-term effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Multivariate Analysis</topic><topic>Osteoporosis. Osteomalacia. Paget disease</topic><topic>Parathyroid hormone</topic><topic>Prophylaxis</topic><topic>Prospective Studies</topic><topic>renal transplantation</topic><topic>Risk Assessment</topic><topic>Sex Factors</topic><topic>Steroid hormones</topic><topic>steroid minimization</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grenda, Ryszard</creatorcontrib><creatorcontrib>Karczmarewicz, Elżbieta</creatorcontrib><creatorcontrib>Rubik, Jacek</creatorcontrib><creatorcontrib>Matusik, Halina</creatorcontrib><creatorcontrib>Płudowski, Paweł</creatorcontrib><creatorcontrib>Kiliszek, Małgorzata</creatorcontrib><creatorcontrib>Piskorski, Jarosław</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Pediatric transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grenda, Ryszard</au><au>Karczmarewicz, Elżbieta</au><au>Rubik, Jacek</au><au>Matusik, Halina</au><au>Płudowski, Paweł</au><au>Kiliszek, Małgorzata</au><au>Piskorski, Jarosław</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients - a prospective study</atitle><jtitle>Pediatric transplantation</jtitle><addtitle>Pediatr Transplant</addtitle><date>2011-03</date><risdate>2011</risdate><volume>15</volume><issue>2</issue><spage>205</spage><epage>213</epage><pages>205-213</pages><issn>1397-3142</issn><eissn>1399-3046</eissn><abstract>Grenda R, Karczmarewicz E, Rubik J, Matusik H, Płudowski P, Kiliszek M, Piskorski J. Bone mineral disease in children after renal transplantation in steroid‐free and steroid‐treated patients – a prospective study. Pediatr Transplantation 2011: 15:205–213. © 2010 John Wiley & Sons A/S.
: Bone disease may persist after transplantation. Different approaches aiming to ameliorate this problem have been investigated. The aim of the study was to compare the long‐term effect of three medical interventions: (i) two prophylactic oral doses of 50 mg ibandronate; (ii) daily oral dose of 0.25 μg of 1α‐OHD3 (both of these regimens in patients receiving steroids), and (iii) steroid minimization immunosuppressive protocol in patients with no other specific prophylaxis. Patients: A total of 37 children, at a mean age of 13.33 ± 3.49 yr, dialyzed for 15.93 ± 16.7 months before transplantation, were divided into three groups, depending on medical intervention. Bone mineral content and density (BMC, BMD, DXA), serum markers of bone resorption and formation (CTX, P1NP), calcium, phosphate, 25OHD3/1.25 (OH)2D3 and PTH concentration were evaluated during two yr of follow‐up. The mean values of BMD in the whole population and among the three subgroups remained within the age‐ and gender‐matched normal range during follow‐up. Patients from groups II (alphacalcidiol) and III (steroid minimization) showed a significant decrease in BMD Z‐scores over time, and this effect was determined with increasing age using multivariate analysis. Patients receiving two doses of ibandronate maintained unchanged Z‐scores for BMD and BMC over time.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21199211</pmid><doi>10.1111/j.1399-3046.2010.01448.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1397-3142 |
| ispartof | Pediatric transplantation, 2011-03, Vol.15 (2), p.205-213 |
| issn | 1397-3142 1399-3046 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_923203080 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Administration, Oral Adolescent Age Age Factors Analysis of Variance Biological and medical sciences Bisphosphonates Bone Demineralization, Pathologic - diagnosis Bone Demineralization, Pathologic - drug therapy Bone Demineralization, Pathologic - etiology Bone Density - drug effects Bone Density - physiology bone disease Bone diseases Bone mineral content Bone mineral density Bone resorption Calcifediol - administration & dosage Calcium phosphate Child Children Cohort Studies Collagen Diphosphonates - administration & dosage Diseases of the osteoarticular system Dose-Response Relationship, Drug Drug Administration Schedule Dual energy X-ray absorptiometry Female Follow-Up Studies General aspects Humans Ibandronic acid Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Kidney transplantation Kidney Transplantation - adverse effects Kidney Transplantation - methods Long-term effects Male Medical sciences Multivariate Analysis Osteoporosis. Osteomalacia. Paget disease Parathyroid hormone Prophylaxis Prospective Studies renal transplantation Risk Assessment Sex Factors Steroid hormones steroid minimization Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Treatment Outcome |
| title | Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients - a prospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T04%3A24%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20mineral%20disease%20in%20children%20after%20renal%20transplantation%20in%20steroid-free%20and%20steroid-treated%20patients%20-%20a%20prospective%20study&rft.jtitle=Pediatric%20transplantation&rft.au=Grenda,%20Ryszard&rft.date=2011-03&rft.volume=15&rft.issue=2&rft.spage=205&rft.epage=213&rft.pages=205-213&rft.issn=1397-3142&rft.eissn=1399-3046&rft_id=info:doi/10.1111/j.1399-3046.2010.01448.x&rft_dat=%3Cproquest_cross%3E923203080%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=851478170&rft_id=info:pmid/21199211&rfr_iscdi=true |